[Heparin and lipoprotein(a). Observations during hemodialysis]. 1993

P Salvini, and E Maddaloni, and M V Levi della Vida, and A Parma, and M G Corpetti, and M Di Lorenzo
Servizio di Cardiologia A. Cesalpino, Ospedale San Camillo, Roma.

The effect of heparin (bolus e.v. 5.000 I.U.) on blood levels of Lp(a) and other lipids (triglycerides, -HDL, -LDL and total cholesterol, apo A1, apo B100 and apo A1/apo B100) was studied in 15 patients (8 M and 7 F) with chronic renal failure during hemodialysis. Statistically significant reductions of the basal values were found for Lp(a) and the other lipids in the blood taken before the beginning of dialysis, 30 min' after the heparin bolus. The analysis of third blood sample (at the end of the hemodialysis, one hour after the end of the heparin maintenance infusion) showed a rise of HDL and LDL-lipoproteins over the basal values clearly in relation to reduced heparin and plasmatic fraction of the blood. The values of Lp(a) had not so high increase as consequence of more elevated affinity with heparin and of a possible enhanced metabolic rate via lipoprotein lipase. The authors, in agreement with similar changes of Lp(a) and other lipids previously observed in patients with coronary diseases during bypass surgery in extracorporeal circulation or angioplasty, (interventions requiring generous heparin treatment), believe to have now sufficient data for attributing heparin a causal role for the above mentioned effects. The authors stress the needing of other studies better understand the action to mechanisms of heparin and to evaluate possible future clinical applications of this new interesting Lp(a)-clearing effect.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

P Salvini, and E Maddaloni, and M V Levi della Vida, and A Parma, and M G Corpetti, and M Di Lorenzo
January 2003, Scandinavian journal of clinical and laboratory investigation,
P Salvini, and E Maddaloni, and M V Levi della Vida, and A Parma, and M G Corpetti, and M Di Lorenzo
December 2010, BMC nephrology,
P Salvini, and E Maddaloni, and M V Levi della Vida, and A Parma, and M G Corpetti, and M Di Lorenzo
November 1989, Therapeutic drug monitoring,
P Salvini, and E Maddaloni, and M V Levi della Vida, and A Parma, and M G Corpetti, and M Di Lorenzo
January 1985, The Journal of laboratory and clinical medicine,
P Salvini, and E Maddaloni, and M V Levi della Vida, and A Parma, and M G Corpetti, and M Di Lorenzo
April 1984, Clinical nephrology,
P Salvini, and E Maddaloni, and M V Levi della Vida, and A Parma, and M G Corpetti, and M Di Lorenzo
October 1995, ANNA journal,
P Salvini, and E Maddaloni, and M V Levi della Vida, and A Parma, and M G Corpetti, and M Di Lorenzo
October 1982, Blood,
P Salvini, and E Maddaloni, and M V Levi della Vida, and A Parma, and M G Corpetti, and M Di Lorenzo
May 2000, Artificial organs,
P Salvini, and E Maddaloni, and M V Levi della Vida, and A Parma, and M G Corpetti, and M Di Lorenzo
June 1997, Kidney international,
P Salvini, and E Maddaloni, and M V Levi della Vida, and A Parma, and M G Corpetti, and M Di Lorenzo
May 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Copied contents to your clipboard!